Proprietary Drug Development

BOL is engaged in collaborations with universities, academic institutions, and hospitals to develop novel drugs and obtain regulatory approvals in the following therapeutic areas:

  • Immunology and autoimmune indications – multiple sclerosis,  glioblastoma, GVHD, scleroderma, immune thrombocytopenic purpura, endometriosis, Sjorgren’s syndrome
  • CNS related – Parkinson’s disease, Epilepsy, ALS
  • Pain Management – chronic pain, neuropathic diabetic pain, fibromyalgia
  • Gastrointestinal diseases (IBD) – primary biliary cirrhosis, Crohn syndrome, ulcerative colitis
  • Joint ailments – rheumatoid arthritis, osteoarthritis
  • Dermatology – psoriasis, atopic dermatitis, vitiligo